A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy (HBS407).

Trial Profile

A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy (HBS407).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Vincristine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms rALLy
  • Sponsors Spectrum Pharmaceuticals; Talon Therapeutics
  • Most Recent Events

    • 08 Dec 2015 Results of post-hoc analysis (n=44) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Jun 2011 Results have been presented at ASCO-2011 according to a Talon Therapeutics media release. Results were also summarised in the media release.
    • 29 Nov 2010 According to a company media release, Hana Biosciences presented results from this trial at ASH (abstract A2142).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top